← Back to Home

Targeting Cancer Gene Junctions, CRISPR Silences Nine Oncogenic Fusions in Cells

An Australian team used an RNA-targeting CRISPR tool to interrupt the transmission of cancer-driving signals from fusion genes, with effects also seen in leukemia cells carrying drug-resistance mutations. But delivering the tool into tumors in the body remains a hurdle that must be overcome before it can become a treatment.

By SURL BioNews

When two genes are incorrectly joined, they can produce an abnormal protein that continually drives cell growth. That junction may also provide a clue for identifying cancer cells. Using a CRISPR tool specifically designed to cut RNA, an Australian research team silenced the transcripts of nine oncogenic fusion genes in laboratory models, including BCR::ABL1 carrying drug-resistance mutations, suggesting another approach to intervening in fusion gene-driven cancers.

The study was published on October 16 in *Science Advances* and conducted by researchers at institutions including the Peter MacCallum Cancer Centre. The team used the PspCas13b enzyme, paired with guide RNAs spanning fusion junctions, to recognize sequences that appear only after two gene segments are joined. It acts on RNA, which carries genetic information, rather than directly rewriting DNA. A key design requirement is distinguishing abnormal fusion products from the normal transcripts of the individual genes.

According to a summary by *CRISPR Medicine News*, the team's tests of four ABL1 fusion transcripts achieved approximately 80–90% silencing while preserving unfused BCR and ABL1 transcripts. This supports the use of junctions as selective targets, but the ability to distinguish targets in specific cell experiments does not establish safety across all normal human tissues.

In a K562 leukemia cell model, the researchers further observed that reducing BCR::ABL1 suppressed STAT5 and ERK signaling associated with cell growth, halted cell proliferation, and induced apoptosis and differentiation toward the red blood cell lineage. These responses also occurred in a cell line carrying the T315I mutation and resistant to dasatinib. Some other BCR::ABL1 variants resistant to asciminib could also be silenced. The findings support the possibility that targeting RNA junctions could bypass some mutations that affect drug action, but they do not establish that it can overcome all mechanisms of drug resistance.

RNA does not necessarily disappear completely after cleavage. The study found that some products had internal deletions near the cleavage site, resulting in RNA that could not be efficiently translated. This reminds researchers that assessing whether the tool has worked requires more than measuring how much RNA remains; they must also determine whether it can still produce cancer-driving proteins.

Beyond BCR::ABL1, the tests covered fusions including RUNX1::RUNX1T1, NPM::ALK, SS18::SSX1/2, and EWSR1::FLI1. These results show that the same recognition principle can be extended to different fusion targets by changing the guide sequence. However, a substantial gap remains between demonstrating proof of concept for silencing different transcripts and proving that this can control the corresponding cancers.

The research remains limited to laboratory cell models and has not yet progressed to animal or human testing. The next questions are how to deliver the CRISPR tool effectively to cancer cells within the body and whether it can maintain its selectivity in more complex environments. Fusion junctions provide a clear molecular address, but whether the tool can reach that address, exert a sufficient effect, and ensure safety will determine how far this design can go.

References

  1. Peter MacCallum Cancer Centre via Medical Xpress
  2. PubMed / Science Advances
  3. CRISPR Medicine News